Over half of COVID-19 vaccine recipients in a recent study were found to be suffering from some form of health complications one year after taking the shots.

The study, published at ScienceDirect on Nov. 10, examined potential post-COVID-19 vaccination syndrome (PCVS) among vaccinated individuals and assessed their quality of life (QoL). The study was conducted among adults aged 18 and above from India who had received either Bharat Biotech’s COVAXIN or the AstraZeneca COVID-19 vaccines.

Among vaccine recipients, 52.8 percent of individuals were found to have at least 1 PCVS a month after primary vaccination. At 12 months, 64.6 percent reported at least 1 PCVS. Though the quality of life rose at six months following vaccination, it subsequently fell at 12 months.

The overall prevalence of PCVS among individuals vaccinated with AstraZeneca was 65.59 percent compared to COVAXIN’s 59.4 percent.

Among individuals who took booster shots, over eight out of ten reported at least one PCVS, which is far higher than the five in ten people from the unvaccinated group who reported a similar syndrome.